Search form

Home
LoginSubscribe
  • Home
  • Country Intelligence
  • Industry Directory
  • Offsets / IC
  • Tenders
    • Haiti(0/week)
    • Guyana(0/week)
    • Honduras(0/week)
    • Jamaica(0/week)
    • Netherlands Antilles(0/week)
    • View all (0/week)
  • News
    • United States(1130/week)
    • Manufacturing(533/week)
    • Energy(396/week)
    • Technology(1100/week)
    • Other Manufacturing(326/week)
  • Events
  • About us
    • Who we are
    • Our People
    • Partners
    • Contact us
  • LinkedIn
  • Login
  • Twitter
  • Register
  • Home
  • News

YolTech Therapeutics

Apr 28, 2025
YolTech Announces First Clinical Data from Ongoing Investigator-Initiated Trial of YOLT-101, An In-Vivo Base Editing Therapy for Familial Hypercholesterolemia
Feb 25, 2025
YolTech Therapeutics Announces Positive Clinical Data for YOLT-203, an In Vivo Gene Editing Therapy for Primary Hyperoxaluria Type 1 (PH1)
Jan 20, 2025
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for b-Thalassemia
Dec 21, 2024
YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR
Sep 04, 2024
/C O R R E C T I O N -- YolTech Therapeutics/
Sep 04, 2024
YolTech Therapeutics Receives U.S. FDA Rare Pediatric Disease Designation for YOLT-203 in Treating Primary Hyperoxaluria Type 1
Aug 22, 2024
YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World's First In Vivo Gene Editing Therapy for PH1
Jul 11, 2024
First Patient Dosed in Phase I Clinical Trial of YOLT-201
Jun 18, 2024
YolTech and KACTUS Join Forces to Propel Innovative DNA editing system in Greater China
Apr 02, 2024
First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH
Mar 27, 2024
YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean
Mar 13, 2024
YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024
Mar 04, 2024
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
Jan 02, 2024
YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024

Latest News

Jun 12, 2025

Solideon Announces $1.25 Million AFWERX Contract

Jun 12, 2025

HII Leads DefenseTech LIVE Event and Highlights How Mission Technologies is Accelerating Across All Domains

Jun 12, 2025

US Researcher Guihua Yu Wins Global Distinction for Pioneering Solar and Hydrogel Water Technologies

Jun 12, 2025

Rocket Lab Successfully Launches Second Mission for iQPS in Rapid 25 Day Turnaround

Jun 12, 2025

Badger Meter Releases 2024 Sustainability Report

Jun 12, 2025

China Maleic Anhydride Market Review 2019-2024 and Forecasts 2025-2029: Capacity, Supply and Demand,...

Jun 12, 2025

China Bisphenol A Market Review 2019-2024 and Forecasts 2025-2029: Capacity, Supply and Demand, Manufacturers...

Jun 12, 2025

Birch Biosciences Enters into Global Patent License Agreement with NREL to Advance Enzymatic Plastic...

View all News

Agenda

30
September
PortugalTroia, Portugal
Seabed Security, 30 September - 01 October 2025, Troia, Portugal
Seabed Security | 30 September - 01 October 2025 | Troia, Portugal Defence iQ Announces Inaugural Seabed Security...
23
September
United KingdomLondon, UK
Countering Explosive Threat & Demining conference, September 23 - 24, 2025, London, UK
Countering Explosive Threat & Demining conference | September 23 - 24, 2025 | London, UK The Countering Explosive...
View All Events

SUBSCRIBE

to Epicos.com
Please register in order to have access to personalized daily information on world-wide A&D industry developments and business opportunities.
Subscribe

REGISTER

for Epicos.com Newsletter
Sign up for our free newsletters and receive twice a week news and intelligence regarding the Aerospace & Defence Industry, meticulously selected by our editorial team.
Sign Up
Home
  • SIGN UP FOR NEWSLETTER
  • NEWSLETTER ARCHIVE
  • ADVERTISE WITH US
  • CONTACT US
  • PRIVACY POLICY
  • INFORMATION SECURITY POLICY
© 2025 EPICOS
Made by Wedia